Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables
Data from Phase II/III Study Presented at Heart Failure Congress 2009 Demonstrate Promising Safety and Efficacy Results for Relaxin
SAN MATEO¿ Calif.¿ June 1 /PRNewswire/ -- Corthera Inc. today announced that the results and additional statistical analyses conducted from Pre-RELAX-AHF, the Phase...
New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
PHILADELPHIA, May 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE(R) (lisdexamfetamine dimesylate) CII with the proton pump inhibitor (PP...
Task Force Recommends Using Aspirin to Prevent Cardiovascular Disease When the Benefits Outweigh the Harms
ROCKVILLE, Md., March 16 /PRNewswire-USNewswire/ -- Patients and clinicians should consider risk factors -- including age, gender, diabetes, blood pressure, cholesterol levels, smoking and risk of gastrointestinal bleeding -- before deciding whether to use aspirin to prevent heart attacks or strok...
A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe
Pfizer's Axitinib Earns Decision Resources' Gold-Standard for Renal Cell Carcinoma in 2012, According to a New Report from Decision Resources
WALTHAM, Mass., Feb. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare is...
Breast Cancer Patients May Have a New Treatment Option When Cancer Spreads
New procedure could offer a safer, more convenient treatment for spine tumors
LAS VEGAS, Feb. 22 /PRNewswire-USNewswire/ -- For orthopaedic researcher Joyce Keyak, Ph.D., finding ways to battle breast cancer is a personal as well as a professional mission. Her cousin died from the disease sev...
Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
- Femara showed reduced risk of death by 13% (P=0.08), despite inclusion of patients crossing over from tamoxifen to Femara therapy
- In a separate censored analysis excluding patients after they crossed over to Femara, reduction in risk of death was 19%
- Long-term follow-up fro...
Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay
SOUTH SAN FRANCISCO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Monogram
Biosciences, Inc. (Nasdaq: MGRM ) announced today that data presented this
week demonstrated that in Pfizer Inc's (NYSE: PFE ) phase III trial of
Selzentry(TM) (maraviroc) in treatment naive individuals with CCR5-tropic
Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
HONG KONG, July 7 /PRNewswire/ -- OrbusNeich today announced that data
presented recently at the 17th Annual Meeting of the Japanese Society of
Interventional Cardiology demonstrate that the Genous Bio-engineered R
stent has better outcomes when
compared to drug-eluting stents.
Presented by ...
DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin
REYKJAVIK, Iceland, June 30 /PRNewswire-FirstCall/ -- deCODE genetics
(Nasdaq: DCGN ) today announced positive topline results from its latest
clinical pharmacology study of DG041, the company's first-in-class
antagonist of the EP3 receptor for prostaglandin E2, developed as a
Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
Post-hoc analysis of pivotal studies presented at the National Lipid Association's Annual Scientific Sessions
PARSIPPANY, N.J., May 30 /PRNewswire/ -- Daiichi Sankyo, Inc.,
announced today that data from post-hoc analyses of three pivotal studies
demonstrated that the addition...
Totality of Available Data Reaffirms PROCRIT(R) (Epoetin alfa) Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy-Induced Anemia
BRIDGEWATER, N.J., March 11 /PRNewswire/ -- The totality of scientific
data submitted in recent months to the U.S. Food and Drug Administration
(FDA) in preparation for the March 13th Oncologic Drugs Advisory Committee
Meeting (ODAC) reaffirms that erythropoiesis-stimulating agents (ESAs) are
VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
- Post-unblinding analysis of MA-17 trial data provides evidence for
potential benefit of starting Femara up to seven years after finishing tamoxifen
- Femara only member of aromatase inhibitor class with data demonstrating this potential benefit, as publishe...
Zetia Does Not Reduce Carotid Plaque Size When Added to Zocor
BEVERLY HILLS, Calif., Jan. 15 /PRNewswire/ -- Zetia (ezetimibe) "may
not actually prevent heart attacks and strokes," according to the
long-awaited results of the Enhance trial. Typically, patients "take Zetia
in the form of Vytorin (ezetimibe and simvastatin), which combines Zetia
Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
CHICAGO, Oct. 16 /PRNewswire/ -- The Preimplantation Genetic Diagnosis
International Society (PGDIS) is releasing a statement in response to a
Practice Committee Opinion issued today by the American Society for
Reproductive Medicine (ASRM). The rationale for determining chromosomal status in ...
Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
GAITHERSBURG, Md., Sept. 11 /PRNewswire/ -- As the Food and Drug
Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee
(CRDAC) and Drug Safety and Risk Management Advisory Committee (DSRMAC)
meet today to discuss questions related to erythropoiesis-stimulating
agents (ESA's), ...
Tekturna, First New Type of High Blood Pressure Medicine in a
Decade, Provides Additional Blood Pressure Reduction When Used With
* New study results show more patients receiving both Tekturna and
Diovan reached target blood pressure goal compared to those taking
either agent alone
EAST HANOVER, N.J., March 26, 2007 /PRNewswire/ -- Results from
a new study have shown patients taking two Novartis cardiovascular
medicines -- t...
Preterm Infants with Respiratory Distress Syndrome: Incidence Rates
of Death when Treated with Surfactant Replacement Therapies
-- Large multi-year, multi-hospital retrospective database analysis
demonstrates RDS treatment with Curosurf(R) (poractant alfa)
Intratracheal Suspension provides significantly improved neonatal
NAPA, Calif. and PARMA, Italy, May 07, 2007 /PRNewswire/ -- Data
presented today at the Ped...
Investigational Cancer Drug Pertuzumab Shows Promising Results in
Advanced Breast Cancer When Combined with Herceptin
Investigational cancer drug Pertuzumab shows promising results in
advanced breast cancer when
combined with Herceptin Phase III
BASEL, Switzerland, June 4, 2007-Early clinical results from
Roche's trial of the exciting new cancer medicine pertuzumab, a HER
The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved
Progression Free Survival When Given Before and After Surgery in
Patients With Resectable Liver Metastases From Colorectal Cancer
Presentation at ASCO Plenary Session Reports EORTC 40983 (EPOC)
Intergroup Study Results
CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Results of the
randomized phase III EORTC 40983 Intergroup study, or EPOC study,
demonstrate for the first time that peri-operative (pre and post
New Data Show Pfizer's Axitinib Prolonged Overall Survival in
Advanced Pancreatic Cancer When Combined with Standard of Care
CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Pfizer announced today that
axitinib (AG-013736), an investigational oral, selective inhibitor
of VEGFR 1, 2,3 (vascular endothelial growth factor receptors 1, 2,
3) combined with gemcitabine showed a trend towards prolonged
overall survival (OS) in patients ...
OREXIGEN Therapeutics Announces Sustained-Release Formulation of
Zonisamide Shows Improved Tolerability When Compared to Immediate
Orexigen(TM) is evaluating zonisamide SR as a novel component in
EMPATIC(TM) Phase IIb obesity trial
SAN DIEGO, June 07, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM)
Therapeutics, Inc. , a biopharmaceutical company focused on the
treatment of central nervous system disorders with an initial focus
Repros Reports That Proellex Has Demonstrated Superior Efficacy and
Safety in Endometriosis When Compared to Standard of Drug Care
THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - Repros
Therapeutics Inc. (NasdaqGM:RPRX) today released top-line findings
from its six month study of Proellex in the treatment of
endometriosis. This study, conducted in Europe, enrolled 39
premenopausal women and has completed six months of do...
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure
Reduction During Important Early Morning Period When Most Adverse
Cardiovascular Events Occur
- Blood pressure reduction achieved at 8 am versus placebo: - 25
/ - 13 mm Hg (systolic / diastolic, p
- Blood pressure reduction dependent on vaccine dose and induced
antiangiotensin II antibody levels
- Detailed results presented today at the Seventeenth European
Meeting on Hypertension in Mil...
Pixantrone Combination Therapy for First-line Treatment of
Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe
Toxicities Including Heart Damage When Compared to
Positive interim results prompt request for meeting with FDA
SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- Cell
Therapeutics, Inc. (CTI) announced today that interim results of
its phase II/III trial comparing CPOP-R, in which pixantrone is
substituted for doxorubicin in standard CHOP-R first-l...
Regular Yoga Practice Is Associated With Mindful Eating
...hose were aware of why they ate and stopped eating when
full - weighed less than those who ate mindlessly, who ate when
not hungry or in response to anxiety or depression...allenging situations, such as not eating more even when
the food tastes good and not eating...
Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
...Vectibix arm. These data confirm previous findings when
oxaliplatin-based chemotherapy and an anti-EGFR an...with KRAS mutant tumors were negatively affected when
Vectibix was added to a standard chemotherapy regi...ations for existing products, may face competition when
and as they are approved and marketed. Our product...
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
Isis earned $1.4 million of revenue when
Isis sold drug to OncoGenex Pharmaceuticals, Inc. ... transactions, the Company's revenue will decrease when
the $50 million upfront payment Isis received from...that Isis recognized in the second quarter of 2009 when
it sold the stock it held in OncoGenex. OncoGenex...
Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
...mors to the bone, are a serious concern for many advanced cancer patients. when
cancer spreads to the bone, the growing cancer cells weaken and destroy the...t candidates or new indications for existing products, may face competition when
and as they are approved and marketed. Our products may compete against pro...
Project Zero Delay Accelerates Drug's Path to Clinical Trial
...nt is typically 135 days in M. D. Anderson's Phase I Clinical Trial Program when
processing of the protocol starts after IND approval. Zero Delay went from...r pipeline. This achievement is a great example of what can be accomplished when
we pair our first class internal capabilities with the strengths of one of ...
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
... leakage of milk from the breasts, development of breasts in men, or problems with erection.
Some people may feel faint, dizzy, or may pass out when
they stand up or sit up suddenly. Be careful not to get up too quickly. It may help if you get up slowly and sit on the edge of the bed or chair for a...
OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
...herapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. when
bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemothera...
British Woman Celebrates a Year of Living Cancer-Free
...king five days a week from 9 to 5. I've been feeling fine," Ms. Scott said.
Her good health and good mood mark a sharp change from how she felt when
she was diagnosed with acute myeloid leukemia (AML) four years ago. AML is a cancer of the myeloid line of blood cells and the most common acute leuke...
Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window
...CA RATON, Fla., July 30 /PRNewswire-USNewswire/ -- when
minimally invasive endovascular (through the vesse... from stroke treatment. Thus, continued Nogueira, when
brain imaging studies revealed that a significa...ge and the overall mortality rate was 22 percent. when
analyzing what factors were most closely associate...
FDA Advisory Committee Votes in Favor of SAPHRIS(R) (asenapine) for Acute Bipolar I Disorder and Acute Schizophrenia
...atients starting treatment and those who need alternative treatment options when
switching or re-initiating therapy. We will continue to work with FDA to b...ects. Poor tolerability frequently leads to treatment discontinuation even when
the treatment is providing some benefit. To help manage this challenge, pa...
Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk
...dy to-date looking at how these drugs impact breast cancer recurrence rates when
taken with tamoxifen.
Antidepressants are often prescribed when
women receiving tamoxifen are depressed, or to treat hot flashes -- a commo...
Is Your Hair Taking a Break?
... anywhere from three to nine months. The key is determining the trigger and when
it occurred in relation to the hair loss."
An au...ne form of hair loss that can affect men and women, alopecia areata, occurs when
the body's white blood cells attack the hair follicles and put them to slee...
Estrogen Getting Cool Reception From Dermatologists for Mixed Results in Improving Appearance of Skin
...ation of photodamaged skin and the potential risks when
used long-term outweigh any potential skin benefit...o, reviewed studies that demonstrate mixed results when
examining whether or not estrogen improves the app..., water retention and elasticity. During pregnancy when
estrogen levels are at their highest, women experi...
Diabetes Gene Raises Odds of Lower Birth Weight
...ent of type 2 diabetes in later life."
Type 2 diabetes occurs either when
the pancreas produces too little insulin or when
the body cannot efficiently use the insulin that is produced. Formerly cal...
Pennsylvania Agriculture Department Issues Quarantine for Allegheny County Horse Stable
...days has elapsed without relevant clinical signs in any horses. At that point, all horses will be tested for EHV-1 and the quarantine will be released when
all horses test negative.
The attending veterinarian at Rolling Hills Ranch recognized symptoms in several horses consistent with the neurolog...
Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease
... their disease."
Women like Olmsted Falls resident Pat Lindamood know all too well the impacts of PMO. Lindamood realized she had osteoporosis when
her dentist refused to work on her due to the frailty of her jaw. She quickly sought treatment from area doctor, Chad Deal, M.D. and, thanks to her ac...